Norovirus Infection Management

Introduction to Norovirus

The Centers for Disease Control and Prevention recommends that norovirus infection, characterized by acute onset of vomiting, watery diarrhea, nausea, and abdominal cramps, should not be treated with loperamide, as it is a self-limited viral gastroenteritis that resolves without antimotility therapy, and using loperamide provides no mortality or morbidity benefit while potentially masking dehydration and prolonging viral shedding 1, 2

Norovirus gastroenteritis is typically resolved within 1-3 days in otherwise healthy persons, with approximately 10% of patients requiring medical attention for dehydration management with oral or intravenous fluids 1, 2
The primary treatment is oral rehydration therapy, not symptom suppression, as loperamide does not address the underlying viral infection or improve clinical outcomes 1

The American Academy of Pediatrics and the World Health Organization recommend prioritizing aggressive oral rehydration as the cornerstone of norovirus management, with administration of oral rehydration solution (ORS) as first-line therapy for mild to moderate dehydration 1, 2
Consider antiemetics (ondansetron) to facilitate oral rehydration if vomiting is severe and impairing fluid intake in patients >4 years old 3
Monitor for dehydration signs, particularly in young children, elderly persons, and hospitalized patients who may have prolonged illness lasting 4-6 days 1, 2
Implement strict infection control measures, including handwashing with soap and water and environmental disinfection with chlorine-based products 1

High fever (>38.5°C) contraindicates loperamide use, as it suggests invasive bacterial infection where slowing motility allows bacterial proliferation and toxin accumulation 4
Bloody stools indicate inflammatory or invasive diarrhea, where loperamide is explicitly contraindicated and increases risk of hemolytic uremic syndrome with STEC 4
Children under 18 years should never receive loperamide for acute diarrhea due to risks of respiratory depression and serious cardiac adverse reactions 4